ArriVent BioPharma (AVBP, Financial) has caught attention as Jones Trading initiates coverage on the stock, assigning a 'Buy' rating. The announcement was made by analyst Soumit Roy on May 20, 2025.
In addition to the positive rating, Jones Trading has set a price target of $40.00 USD for ArriVent BioPharma (AVBP, Financial). This marks the initial coverage and target setting for the company by this particular analyst.
Investors should note that prior to this coverage, there were no existing ratings or price targets from Jones Trading for ArriVent BioPharma (AVBP, Financial). The news could potentially impact trading activity and investor interest in the company's stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for ArriVent BioPharma Inc (AVBP, Financial) is $39.43 with a high estimate of $45.00 and a low estimate of $36.00. The average target implies an upside of 96.60% from the current price of $20.06. More detailed estimate data can be found on the ArriVent BioPharma Inc (AVBP) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, ArriVent BioPharma Inc's (AVBP, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
